Bipolar Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major bipolar disorder markets reached a value of US$ 3.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.8 Billion by 2034, exhibiting a growth rate (CAGR) of 1.82% during 2024-2034.
The bipolar disorder market has been comprehensively analyzed in IMARC's new report titled "Bipolar Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bipolar disorder, also known as manic-depressive illness, refers to a mental health condition that causes extreme shifts in mood, energy, and activity levels. It can be classified into several types based on the pattern and severity of symptoms, including bipolar I, bipolar II, cyclothymic, and unspecified bipolar disorder. Individuals may experience episodes of mania or hypomania, during which they feel unusually elated, irritable, or energetic, and engage in impulsive or risky behaviors. They might also go through depressive periods where they feel sad and depressed and lose interest in things they used to enjoy. In some cases, people with bipolar disorder may exhibit psychotic indications like hallucinations or delusions. The diagnosis of the ailment is typically made by a mental health professional, such as a psychiatrist or psychologist, through a comprehensive assessment of the person's symptoms, medical history, and family history. This evaluation may include a physical exam, blood investigations, and psychological tests to rule out other conditions that may cause similar indications.
The increasing cases of neurochemical imbalances, which can cause symptoms of mania or depression, are primarily driving the bipolar disorder market. Furthermore, the rising prevalence of various associated risk factors, such as genetic predisposition, trauma, stress, substance abuse, etc., is also propelling the market growth. In addition to this, the escalating utilization of antipsychotic medications, including olanzapine and risperidone, for managing manic episodes is creating a positive outlook for the market. Moreover, the inflating usage of cognitive-behavioral therapy (CBT) to assist patients in developing coping skills and identifying triggers for their symptoms, which can help them manage their condition more effectively, is also bolstering the market growth. Apart from this, the emerging popularity of electroconvulsive therapy, since it aids in lowering the indications of depression and mania in individuals with bipolar disorder, is acting as another significant growth-inducing factor. Additionally, the introduction of novel imaging technologies, such as functional magnetic resonance imaging (fMRI), for studying the brain and understanding the neural pathways associated with the ailment is expected to drive the bipolar disorder market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the bipolar disorder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bipolar disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bipolar disorder market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bipolar disorder market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the bipolar disorder market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current bipolar disorder marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the bipolar disorder market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the bipolar disorder market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the bipolar disorder market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of bipolar disorder across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of bipolar disorder by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of bipolar disorder by gender across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of bipolar disorder by type across the seven major markets?
How many patients are diagnosed (?2018-2034?) with bipolar disorder across the seven major markets?
What is the size of the bipolar disorder patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of bipolar disorder?
What will be the growth rate of patients across the seven major markets?
Bipolar Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for bipolar disorder drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bipolar disorder market?
What are the key regulatory events related to the bipolar disorder market?
What is the structure of clinical trial landscape by status related to the bipolar disorder market?
What is the structure of clinical trial landscape by phase related to the bipolar disorder market?
What is the structure of clinical trial landscape by route of administration related to the bipolar disorder market?
The bipolar disorder market has been comprehensively analyzed in IMARC's new report titled "Bipolar Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bipolar disorder, also known as manic-depressive illness, refers to a mental health condition that causes extreme shifts in mood, energy, and activity levels. It can be classified into several types based on the pattern and severity of symptoms, including bipolar I, bipolar II, cyclothymic, and unspecified bipolar disorder. Individuals may experience episodes of mania or hypomania, during which they feel unusually elated, irritable, or energetic, and engage in impulsive or risky behaviors. They might also go through depressive periods where they feel sad and depressed and lose interest in things they used to enjoy. In some cases, people with bipolar disorder may exhibit psychotic indications like hallucinations or delusions. The diagnosis of the ailment is typically made by a mental health professional, such as a psychiatrist or psychologist, through a comprehensive assessment of the person's symptoms, medical history, and family history. This evaluation may include a physical exam, blood investigations, and psychological tests to rule out other conditions that may cause similar indications.
The increasing cases of neurochemical imbalances, which can cause symptoms of mania or depression, are primarily driving the bipolar disorder market. Furthermore, the rising prevalence of various associated risk factors, such as genetic predisposition, trauma, stress, substance abuse, etc., is also propelling the market growth. In addition to this, the escalating utilization of antipsychotic medications, including olanzapine and risperidone, for managing manic episodes is creating a positive outlook for the market. Moreover, the inflating usage of cognitive-behavioral therapy (CBT) to assist patients in developing coping skills and identifying triggers for their symptoms, which can help them manage their condition more effectively, is also bolstering the market growth. Apart from this, the emerging popularity of electroconvulsive therapy, since it aids in lowering the indications of depression and mania in individuals with bipolar disorder, is acting as another significant growth-inducing factor. Additionally, the introduction of novel imaging technologies, such as functional magnetic resonance imaging (fMRI), for studying the brain and understanding the neural pathways associated with the ailment is expected to drive the bipolar disorder market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the bipolar disorder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bipolar disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bipolar disorder market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bipolar disorder market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the bipolar disorder market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current bipolar disorder marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the bipolar disorder market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the bipolar disorder market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the bipolar disorder market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of bipolar disorder across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of bipolar disorder by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of bipolar disorder by gender across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of bipolar disorder by type across the seven major markets?
How many patients are diagnosed (?2018-2034?) with bipolar disorder across the seven major markets?
What is the size of the bipolar disorder patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of bipolar disorder?
What will be the growth rate of patients across the seven major markets?
Bipolar Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for bipolar disorder drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bipolar disorder market?
What are the key regulatory events related to the bipolar disorder market?
What is the structure of clinical trial landscape by status related to the bipolar disorder market?
What is the structure of clinical trial landscape by phase related to the bipolar disorder market?
What is the structure of clinical trial landscape by route of administration related to the bipolar disorder market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BIPOLAR DISORDER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (?2024-2034?)
4.4 Market Overview (2018-2023) and Forecast (?2024-2034?)
4.5 Competitive Intelligence
5 BIPOLAR DISORDER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BIPOLAR DISORDER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (?2024-2034?)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 BIPOLAR DISORDER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BIPOLAR DISORDER - UNMET NEEDS
10 BIPOLAR DISORDER - KEY ENDPOINTS OF TREATMENT
11 BIPOLAR DISORDER - MARKETED PRODUCTS
11.1 List of Bipolar Disorder Marketed Drugs Across the Top 7 Markets
11.1.1 Saphris (Asenapine) - AbbVie/ Lundbeck A/S/ Meiji Seika Pharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Vraylar (Cariprazine) - Gedeon Richter
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Zyprexa (Olanzapine) - Eli Lilly & Co.
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Seroquel (Quetiapine) - AstraZeneca
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Geodon (Ziprasidone) - Pfizer
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 BIPOLAR DISORDER - PIPELINE DRUGS
12.1 List of Bipolar Disorder Pipeline Drugs Across the Top 7 Markets
12.1.1 Brexpiprazole - Lundbeck/Otsuka
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 BXCL501 - BioXcel Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 JNJ-55308942 - janssen-cilag
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Iloperidone - Vanda Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BIPOLAR DISORDER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BIPOLAR DISORDER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BIPOLAR DISORDER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bipolar Disorder - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (?2024-2034?)
15.2.2 Bipolar Disorder - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (?2024-2034?)
15.3 Market Scenario - United States
15.3.1 Bipolar Disorder - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (?2024-2034?)
15.3.2 Bipolar Disorder - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (?2024-2034?)
15.3.3 Bipolar Disorder - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bipolar Disorder - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (?2024-2034?)
15.4.2 Bipolar Disorder - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (?2024-2034?)
15.4.3 Bipolar Disorder - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bipolar Disorder - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (?2024-2034?)
15.5.2 Bipolar Disorder - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (?2024-2034?)
15.5.3 Bipolar Disorder - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bipolar Disorder - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (?2024-2034?)
15.6.2 Bipolar Disorder - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (?2024-2034?)
15.6.3 Bipolar Disorder - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bipolar Disorder - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (?2024-2034?)
15.7.2 Bipolar Disorder - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (?2024-2034?)
15.7.3 Bipolar Disorder - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bipolar Disorder - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (?2024-2034?)
15.8.2 Bipolar Disorder - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (?2024-2034?)
15.8.3 Bipolar Disorder - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bipolar Disorder - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (?2024-2034?)
15.9.2 Bipolar Disorder - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (?2024-2034?)
15.9.3 Bipolar Disorder - Access and Reimbursement Overview
16 BIPOLAR DISORDER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BIPOLAR DISORDER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BIPOLAR DISORDER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BIPOLAR DISORDER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (?2024-2034?)
4.4 Market Overview (2018-2023) and Forecast (?2024-2034?)
4.5 Competitive Intelligence
5 BIPOLAR DISORDER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BIPOLAR DISORDER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (?2024-2034?)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 BIPOLAR DISORDER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BIPOLAR DISORDER - UNMET NEEDS
10 BIPOLAR DISORDER - KEY ENDPOINTS OF TREATMENT
11 BIPOLAR DISORDER - MARKETED PRODUCTS
11.1 List of Bipolar Disorder Marketed Drugs Across the Top 7 Markets
11.1.1 Saphris (Asenapine) - AbbVie/ Lundbeck A/S/ Meiji Seika Pharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Vraylar (Cariprazine) - Gedeon Richter
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Zyprexa (Olanzapine) - Eli Lilly & Co.
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Seroquel (Quetiapine) - AstraZeneca
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Geodon (Ziprasidone) - Pfizer
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 BIPOLAR DISORDER - PIPELINE DRUGS
12.1 List of Bipolar Disorder Pipeline Drugs Across the Top 7 Markets
12.1.1 Brexpiprazole - Lundbeck/Otsuka
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 BXCL501 - BioXcel Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 JNJ-55308942 - janssen-cilag
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Iloperidone - Vanda Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BIPOLAR DISORDER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BIPOLAR DISORDER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BIPOLAR DISORDER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bipolar Disorder - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (?2024-2034?)
15.2.2 Bipolar Disorder - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (?2024-2034?)
15.3 Market Scenario - United States
15.3.1 Bipolar Disorder - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (?2024-2034?)
15.3.2 Bipolar Disorder - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (?2024-2034?)
15.3.3 Bipolar Disorder - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bipolar Disorder - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (?2024-2034?)
15.4.2 Bipolar Disorder - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (?2024-2034?)
15.4.3 Bipolar Disorder - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bipolar Disorder - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (?2024-2034?)
15.5.2 Bipolar Disorder - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (?2024-2034?)
15.5.3 Bipolar Disorder - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bipolar Disorder - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (?2024-2034?)
15.6.2 Bipolar Disorder - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (?2024-2034?)
15.6.3 Bipolar Disorder - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bipolar Disorder - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (?2024-2034?)
15.7.2 Bipolar Disorder - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (?2024-2034?)
15.7.3 Bipolar Disorder - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bipolar Disorder - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (?2024-2034?)
15.8.2 Bipolar Disorder - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (?2024-2034?)
15.8.3 Bipolar Disorder - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bipolar Disorder - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (?2024-2034?)
15.9.2 Bipolar Disorder - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (?2024-2034?)
15.9.3 Bipolar Disorder - Access and Reimbursement Overview
16 BIPOLAR DISORDER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BIPOLAR DISORDER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BIPOLAR DISORDER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
